Get the Stockscreener App
0.6415
4.28%
-0.0287
Glucotrack Inc stock is traded at $0.6415, with a volume of 685.76K.
It is down -4.28% in the last 24 hours and down -79.31% over the past month.
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.
See More
Previous Close:
$0.6702
Open:
$0.651
24h Volume:
685.76K
Relative Volume:
0.23
Market Cap:
$6.98M
Revenue:
-
Net Income/Loss:
$-8.74M
P/E Ratio:
-0.3129
EPS:
-2.05
Net Cash Flow:
$-8.25M
1W Performance:
-49.88%
1M Performance:
-79.31%
6M Performance:
-97.06%
1Y Performance:
-97.21%
1-Day Range:
$0.60
$0.6572
1-Week Range:
$0.485
$2.13
52-Week Range:
$0.485
$99.00
Glucotrack Inc Stock (GCTK) Company Profile
Name
Glucotrack Inc
Sector
Industry
Phone
972 (8) 675-7878
Address
301 RT 17 NORTH, RUTHERFORD
Compare GCTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.6415 | 6.98M | 0 | -8.74M | -8.25M | -2.05 |
|
ISRG
Intuitive Surgical Inc
|
587.00 | 209.89B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.97 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
90.13 | 45.33B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
236.16 | 34.84B | 4.93B | 1.25B | 1.38B | 8.47 |
|
WST
West Pharmaceutical Services Inc
|
321.11 | 23.97B | 2.88B | 499.60M | 321.60M | 6.74 |
Glucotrack Inc Stock (GCTK) Latest News
GlucoTrack (NASDAQ:GCTK) Implements Reverse Stock Split and Completes First Human Clinical Study – What Investors Need to Know - Armenian Reporter
**GlucoTrack, Inc. Announces Pricing of $3.0 Million Public Offering** - Defense World
Offerings News Live Feed - StockTitan
Understanding the Risks of Investing in GlucoTrack Inc (GCTK) - Knox Daily
Glucotrack Prices $3 Million Public Offering to Fund Expansion - Yahoo Finance
Glucotrack’s 3-year diabetes sensor implant clears initial human safety trial - Fierce Biotech
GlucoTrack’s $3.03M Stock Offering Agreement Announced - TipRanks
Glucotrack reports success in first human glucose monitor trial By Investing.com - Investing.com South Africa
Glucotrack soars on completion of first human clinical study of continuous blood glucose monitor - MSN
GCTKGlucoTrack, Inc. Latest Stock News & Market Updates - StockTitan
Market cap of GlucoTrack Inc [GCTK] reaches 8.86M – now what? - The DBT News
Glucotrack, Inc. Announces Pricing Of $3.0 Million Public Offering -February 04, 2025 at 01:59 pm EST - Marketscreener.com
Glucotrack hits trial success for direct blood measuring CGM - Medical Device Network
Glucotrack sets terms for $3 million public stock offering - Investing.com
GlucoTrack Prices $3 Million Public Offering; Shares Fall -February 04, 2025 at 12:48 pm EST - Marketscreener.com
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering - The Manila Times
Volcon, Inc. and GlucoTrack, Inc. See Massive Gains, While Omega Therapeutics and Universe Pharmaceuticals Struggle – market - HPBL
Diabetes Tech Pioneer Glucotrack Raises Fresh Capital: Key Details of $3M Share Offering Revealed - StockTitan
Glucotrack completes first-in-human continuous blood glucose monitor implant study - Mass Device
GlucoTrack Announces Reverse Stock Split and Clinical Study Success - TipRanks
Glucotrack completes first-in-human CGM implant study - Drug Delivery Business News
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor - The Manila Times
Glucotrack reports success in first human glucose monitor trial - Investing.com
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous - The Bakersfield Californian
Revolutionary Blood Glucose Monitor Shows Promise: Direct Blood Measurement Could Transform Diabetes Care - StockTitan
GlucoTrack Inc: -98.71% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
Glucotrack, Inc. Announces 1-for-20 Reverse Stock Split - Defense World
GCTK Stock Plummets to 52-Week Low of $0.06 Amid Market Turbulence - MSN
GlucoTrack Announces Resignation of Chief Financial Officer and Appointment of Peter Wulff as Replacement**WASHINGTON, D.C. 2025 – GlucoTrack, Inc. (NASDAQ: GCTK) recently disclosed on January 27, 2025, that James Cardwell, the Chief Financial - Defense World
Glucotrack announces 1-for-20 reverse stock split - Investing.com India
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
GlucoTrack Announces 1-for-20 Reverse Stock Split - TipRanks
Glucotrack to execute 1-for-20 reverse stock split - MSN
GlucoTrack, Inc. Announces Chief Financial Officer Changes -January 29, 2025 at 09:00 am EST - Marketscreener.com
Glucotrack announces 1-for-20 reverse stock split By Investing.com - Investing.com Canada
Glucotrack's Strategic Move: 1-for-20 Reverse Split Could Save Nasdaq Listing - StockTitan
Glucotrack Appoints Peter C. Wulff as CFO - citybiz
GlucoTrack Appoints Peter Wulff as CFO -January 29, 2025 at 11:41 am EST - Marketscreener.com
GlucoTrack Strengthens Leadership with New CFO Appointment - TipRanks
35-Year MedTech Finance Veteran Joins Glucose Monitor Innovator as New CFO - StockTitan
How Is The Market Feeling About GlucoTrack? - Benzinga
Headwater Exploration (OTCMKTS:CDDRF) Trading 3.1% Higher – Should You Buy? - Defense World
Cuisine Solutions (OTCMKTS:CUSI) Shares Down 0.5% – Here’s Why - Defense World
StockNews.com Upgrades Park Aerospace (NYSE:PKE) to Buy - Defense World
Interfor (TSE:IFP) Given New C$26.00 Price Target at Raymond James - Defense World
Li Ning (OTCMKTS:LNNGF) Trading 3.3% Higher – Here’s What Happened - Defense World
John Bean Technologies (NYSE:JBT) Now Covered by StockNews.com - Defense World
Old Second Bancorp Declares Quarterly Cash Dividend On January 21, 2025, Old Second Bancorp, Inc. (NASDAQ: OSBC) announced through a Form 8-K filing that its Board of Directors has approved a cash dividend of $0.06 per share. The dividend is set to - Defense World
Jupiter Wellness (NASDAQ:JUPW) Reports Regulation FD Disclosure Concerning Safety Shot, Inc. - Defense World
Ark Restaurants (NASDAQ:ARKR) Coverage Initiated by Analysts at StockNews.com - Defense World
NextSource Materials (OTCMKTS:NSRCF) Stock Price Up 7.1% – Time to Buy? - Defense World
Glucotrack Inc Stock (GCTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):